hydrochlorothiazide has been researched along with Impaired Glucose Tolerance in 5 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressure, prevents glucose intolerance and improves control of blood pressure compared with montherapy with either drug." | 5.22 | Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, G; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2016) |
| " The authors investigated the effects of varying doses of hydrochlorothiazide (HCTZ) on arterial elasticity and metabolic parameters in patients with hypertension (HTN), HTN and impaired fasting glucose (HTN+IFG), and HTN and type 2 diabetes mellitus (HTN+DM)." | 3.74 | Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance. ( Asherov, J; Boaz, M; Davidovitz, I; Gavish, D; Shargorodsky, M; Zimlichman, R, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, MJ | 1 |
| Gong, Y | 1 |
| Hou, W | 1 |
| Hall, K | 1 |
| Schmidt, SO | 1 |
| Curry, RW | 1 |
| Beitelshees, AL | 1 |
| Chapman, A | 1 |
| Turner, ST | 1 |
| Schwartz, GL | 1 |
| Bailey, K | 1 |
| Boerwinkle, E | 1 |
| Gums, JG | 1 |
| Cooper-DeHoff, RM | 1 |
| Johnson, JA | 1 |
| Brown, MJ | 2 |
| Williams, B | 2 |
| MacDonald, TM | 2 |
| Caulfield, M | 1 |
| Cruickshank, JK | 2 |
| McInnes, G | 2 |
| Sever, P | 2 |
| Webb, DJ | 2 |
| Salsbury, J | 2 |
| Morant, S | 1 |
| Ford, I | 2 |
| Morant, SV | 1 |
| Caulfield, MJ | 1 |
| Mackenzie, IS | 1 |
| Padmanabhan, S | 1 |
| Shargorodsky, M | 1 |
| Boaz, M | 1 |
| Davidovitz, I | 1 |
| Asherov, J | 1 |
| Gavish, D | 1 |
| Zimlichman, R | 1 |
| Byington, RP | 1 |
| Craven, TE | 1 |
| Furberg, CD | 1 |
| Pahor, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With[NCT00797862] | Phase 3 | 1,254 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -13.64 |
| Aliskiren Start-Amlodipine Add On | -13.22 |
| Amlodipine Start-Aliskiren Add On | -12.25 |
Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.96 |
| Aliskiren Start-Amlodipine Add On | -12.96 |
| Amlodipine Start-Aliskiren Add On | -11.62 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -27.37 |
| Aliskiren Start-Amlodipine Add On | -26.34 |
| Amlodipine Start-Aliskiren Add On | -25.52 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 & 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msSBP was a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -26.42 |
| Aliskiren Start-Amlodipine Add On | -25.75 |
| Amlodipine Start-Aliskiren Add On | -24.32 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.39 |
| Aliskiren Start-Amlodipine Add On | -8.37 |
| Amlodipine Start-Aliskiren Add On | -9.02 |
Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks, and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -25.34 |
| Aliskiren Start-Amlodipine Add On | -17.94 |
| Amlodipine Start-Aliskiren Add On | -19.81 |
Systolic & Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP <140 mmHg and msDBP <90 mmHg) at weeks 8, 16, 24 & 32 endpoints. (NCT00797862)
Timeframe: Baseline to week 8, 16, 24 and 32 endpoints
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Week 8 endpoint | Week 16 endpoint | Week 24 endpoint | Week 32 endpoint | |
| Aliskiren Start-Amlodipine Add On | 22.8 | 33.3 | 62.8 | 59.0 |
| Aliskiren+Amlodipine | 46.5 | 65.9 | 63.4 | 61.6 |
| Amlodipine Start-Aliskiren Add On | 25.2 | 40.9 | 57.8 | 53.4 |
4 trials available for hydrochlorothiazide and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Atenolol; Blood Glucose; Coh | 2014 |
Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amiloride; Blood Glucose; Blood Pressure; Clinical Protocols; Diuretics; Do | 2015 |
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.
Topics: Aged; Amiloride; Diuretics; Double-Blind Method; Female; Glucose Intolerance; Humans; Hydrochlorothi | 2016 |
Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events.
Topics: Arteriosclerosis; Blood Glucose; Calcium Channel Blockers; Cardiovascular Diseases; Carotid Artery D | 1997 |
1 other study available for hydrochlorothiazide and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance.
Topics: Arteries; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Elasticity; Female; Glucose Intolera | 2007 |